A glioma is a tumor of the central nervous system that starts from glia cells. Susceptibility may be associated with variants in the IDH1 gene.
1. |
Piccirillo SG et al. (2006) Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. |
2. |
Singh D et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. |
3. |
Jones DT et al. (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. |
4. |
Parsons DW et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. |
5. |
Yan H et al. (2009) IDH1 and IDH2 mutations in gliomas. |
6. |
Dubbink HJ et al. (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. |
7. |
Bralten LB et al. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. |
8. |
Flavahan WA et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. |
9. |
Bredel M et al. (2011) NFKBIA deletion in glioblastomas. |
10. |
None (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. |
11. |
Thuwe I et al. (1979) Familial brain tumour. |
12. |
de Tribolet N et al. (1979) Familial gliomas. |
13. |
von Motz IP et al. (1977) Astrocytoma in three sisters. |
14. |
Clarenbach P et al. (1979) Simultaneous clinical manifestation of subependymoma of the fourth ventricle in identical twins. Case report. |
15. |
Ransom DT et al. (1992) Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. |
16. |
von Deimling A et al. (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. |
17. |
Wong AJ et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. |
18. |
Olopade OI et al. (1992) Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. |
19. |
Sainati L et al. (1992) Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas? |
20. |
Griffin CA et al. (1992) Chromosome abnormalities in low-grade central nervous system tumors. |
21. |
Bigner SH et al. (1990) Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. |
22. |
Duhaime AC et al. (1989) Simultaneous presentation of glioblastoma multiforme in siblings two and five years old: case report. |
23. |
Fujimoto M et al. (1989) Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme. |
24. |
Geraghty AV et al. (1989) Prenatal diagnosis of fetal glioblastoma multiforme. |
25. |
el-Azouzi M et al. (1989) Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. |
26. |
Chemke J et al. (1985) Familial glioblastoma multiforme without neurofibromatosis. |
27. |
Heuch I et al. (1986) Glioblastoma multiforme in three family members, including a case of true multicentricity. |
28. |
Honan WP et al. (1987) Familial subependymomas. |
29. |
Bigner SH et al. (1988) Specific chromosomal abnormalities in malignant human gliomas. |
30. |
Munoz DG et al. (1988) Cerebral malignant tumors with ependymal and choroidal differentiation in two siblings. |
31. |
Vieregge P et al. (1987) Familial glioma: occurrence within the "familial cancer syndrome" and systemic malformations. |
32. |
Leblanc R et al. (1986) Familial mixed oligodendrocytic-astrocytic gliomas. |
33. |
Henn W et al. (1986) Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines. |
34. |
Isamat F et al. (1974) Genetic implications of familial brain tumors. |
35. |
Armstrong RM et al. (1969) Familial gliomas. |
36. |
None (1971) Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960-67. |
37. |
Downward J et al. () Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. |
38. |
Schianchi P et al. (1980) Familial brain tumors: rhombencephalon-astrocytoma grade I in father and son. |
39. |
Chen P et al. (1995) Constitutional p53 mutations associated with brain tumors in young adults. |
40. |
Fults D et al. (1993) Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme. |
41. |
Ryken TC et al. (1994) Familial occurrence of subependymoma. Report of two cases. |
42. |
Kyritsis AP et al. (1994) Germline p53 gene mutations in subsets of glioma patients. |
43. |
Karlbom AE et al. (1993) Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10. |
44. |
Bögler O et al. (1995) The p53 gene and its role in human brain tumors. |
45. |
von Deimling A et al. (1995) Molecular pathways in the formation of gliomas. |
46. |
Kimmelman AC et al. (1996) Loss of heterozygosity of chromosome 10p in human gliomas. |
47. |
Chattopadhyay P et al. (1997) Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours. |
48. |
Mollenhauer J et al. (1997) DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. |
49. |
Chernova OB et al. (1998) A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. |
51. |
Smith JS et al. (2000) A transcript map of the chromosome 19q-arm glioma tumor suppressor region. |
52. |
Frederick L et al. (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. |
53. |
Ueki K et al. (1997) ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. |
54. |
Tachibana I et al. (2000) Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. |
55. |
Holland EC et al. (2000) Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. |
56. |
Reilly KM et al. (2000) Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. |
57. |
Esteller M et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. |
58. |
Malmer B et al. (2001) Genetic epidemiology of glioma. |
59. |
de Andrade M et al. (2001) Segregation analysis of cancer in families of glioma patients. |
60. |
Nishimoto A et al. (2001) Functional evidence for a telomerase repressor gene on human chromosome 10p15.1. |
61. |
Marie Y et al. (2001) OLIG2 as a specific marker of oligodendroglial tumour cells. |
62. |
Hoang-Xuan K et al. (2001) Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. |
63. |
Jin W et al. (2000) p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas. |
64. |
Pollack IF et al. (2002) Expression of p53 and prognosis in children with malignant gliomas. |
65. |
Gutmann DH et al. (2002) Mouse glioma gene expression profiling identifies novel human glioma-associated genes. |
66. |
Cartron PF et al. (2002) The expression of a new variant of the pro-apoptotic molecule Bax, Baxpsi, is correlated with an increased survival of glioblastoma multiforme patients. |
67. |
Staal FJ et al. (2002) A novel germline mutation of PTEN associated with brain tumours of multiple lineages. |
68. |
Hu J et al. (2002) High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours. |
69. |
Leuraud P et al. (2003) Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1. |
70. |
KJELLIN K et al. (1960) The occurrence of brain tumors in several members of a family. |
71. |
PARKINSON D et al. (1962) Oligodendrogliomas. Simultaneous appearance in frontal lobes of siblings. |
72. |
Yokota T et al. (2003) A family with spinal anaplastic ependymoma: evidence of loss of chromosome 22q in tumor. |
73. |
Hegi ME et al. (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. |
74. |
Aldape KD et al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. |
75. |
Reilly KM et al. (2004) Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. |
76. |
Stupp R et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. |
77. |
Hegi ME et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. |
78. |
Liang Y et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. |
79. |
Mellinghoff IK et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. |
80. |
Bao S et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. |
81. |
Pfister S et al. (2008) BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. |
82. |
Savaskan NE et al. (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. |
83. |
Blumenthal DT et al. (2008) Familiality in brain tumors. |
84. |
Zheng H et al. (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. |
85. |
El Hallani S et al. (2009) TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. |
86. |
De Carli E et al. (2009) IDH1 and IDH2 mutations in gliomas. |
87. |
Yu J et al. (2009) Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. |
88. |
Carro MS et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. |
89. |
Kyritsis AP et al. (2010) Inherited predisposition to glioma. |
90. |
Labussière M et al. (2010) All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. |
91. |
Sheng Z et al. (2010) A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. |
92. |
Johnson RA et al. (2010) Cross-species genomics matches driver mutations and cell compartments to model ependymoma. |
93. |
Wang R et al. (2010) Glioblastoma stem-like cells give rise to tumour endothelium. |
94. |
Ricci-Vitiani L et al. (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. |
95. |
Bettegowda C et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. |
96. |
Schwartzentruber J et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. |
97. |
Wu G et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. |
98. |
Muller FL et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. |
99. |
Lewis PW et al. (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. |
100. |
Frattini V et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma. |
101. |
Parker M et al. (2014) C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. |
102. |
Mack SC et al. (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. |
103. |
Funato K et al. (2014) Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. |
104. |
Kim D et al. (2015) SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. |
105. |
et al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. |
106. |
Eckel-Passow JE et al. (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. |
107. |
Jahani-Asl A et al. (2016) Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. |
108. |
OMIM.ORG article Omim 137800 |